




# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MBWILSON@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3035

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

November 26, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
November 26, 2003	
Date	Mark B. Wilson

MS DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RE: *U.S. Patent Application No. 10/667,534 entitled "METHOD FOR THE DEVELOPMENT OF AN HIV VACCINE" – Adan Rios*  
*Our reference: RIOS:004USC2*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/RIOS:004USC2.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Mark B. Wilson  
Reg. No. 37,259

MBW/cas  
Encl.: As noted

25356379.1



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Adan Rios

Serial No.: 10/667,534


Filed: September 22, 2003

For: METHOD FOR THE DEVELOPMENT OF  
AN HIV VACCINE

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: RIOS:004USC2



**INFORMATION DISCLOSURE STATEMENT**

**MS DD**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/RIOS:004USC2.

This application is a divisional application of Serial No. 09/638,833, filed August 14, 2000 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/638,833.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 26, 2003

Form PTO-1449 (modified)

Atty. Docket No.

RIOS:004USC2

Serial No.

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Group:

1648

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,849,475	12/15/98	Rovinski <i>et al.</i>	435	5	5/30/95
	A2	5,919,458	7/6/99	Aldovini <i>et al.</i>	424	188.1	6/7/95
	A3	6,017,543	1/25/00	Salk <i>et al.</i>	424	208.1	6/5/95
	A4	6,080,408	6/27/00	Rovinski <i>et al.</i>	424	188.1	6/7/95

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<del>✓</del>	<del>C1</del>	<del>"Aronex HIV inhibitor nears patent issuance," Reuters NewMedia, Inc., February 23, 1996, Abstract.</del>
<del>✓</del>	<del>C2</del>	<del>"Aronex reports preliminary clinical results on its HIV integrase inhibitor, zintevir (TM)," PR Newswire, November, 12, 1996, Abstract.</del>
<del>✓</del>	C3	Ada, "An Immunologist's View of HIV Infection," <i>Textbook of AIDS Medicine</i> , Chapter 6, pp. 77-87, Brothier <i>et al.</i> , eds., Williams & Wilkins, Baltimore, MD, 1994.
<del>✓</del>	C4	Ada, "Modern vaccines, the immunological principles of vaccination," <i>The Lancet</i> , 335:523-526, 1990.
<del>✓</del>	C5	Albert, <i>et al.</i> , "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs," <i>Nature</i> , 392:86-89, 1998.
<del>✓</del>	C6	Aldrovandi <i>et al.</i> , "The SCID-hu mouse as a model for HIV-1 infection," <i>Nature</i> , 363:732-736, 1993.
<del>✓</del>	C7	Amadori <i>et al.</i> , "The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats," <i>Semin Immunol.</i> 8:249-254, 1996.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED:

04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.  
RIOS:004USC2Serial No.  
10/667,534

List of Patents and Publications for Applicant's

Applicant  
Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
September 22, 2003Group: 1648  
~~Unknown~~U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
* ↓	C8	Baba <i>et al.</i> , "Pathogenicity of live, attenuated hiv after mucosal infection of neonatal macaques," <i>Science</i> , 267:1820-1825, 1995.
* ↓	C9	Bachmann and Zinkernagel, "Neutralizing antiviral b cell responses," <i>Annu. Rev. Immunol.</i> , 15:235-270, 1997.
* ↓	C10	Balter, "A cluster of Europe's aids research stars," <i>Science</i> , 280:1862, 1998c.
* ↓	C11	Balter, "Duo brings hope of immune restoration," <i>Science</i> , 280:1861, 1998b.
* ↓	C12	Balter, "Global program struggles to stem the flood of new cases," <i>Science</i> , 280:1863-1864, 1998d.
* ↓	C13	Balter, "HIV incidence: 'more serious than we imagined'," <i>Science</i> , 280:1864, 1998e.
* ↓	C14	Balter, "Modest briton stirs up storm with views on role of CTLs," <i>Science</i> , 280:1860-1861, 1998a.
* ↓	C15	Balter, "T cell production slowed, not exhausted?" <i>Science</i> , 283(5400):305-306, 1999.
* ↓	C16	Baltimore, "Lessons from people with nonprogressive hiv infection," <i>The New England J. of Med.</i> , 332:259-260, 1995.
* ↓	C17	Banchereau and Steinman, "Dendritic cells and the control of immunity," <i>Nature</i> , 392:245-252, 1998.
* ↓	C18	Barnard <i>et al.</i> , "The thiocarboxanilide nonnucleoside uc781 is a tight-binding inhibitor of hiv-1 reverse transcriptase," <i>Biochem.</i> , 36:7786-7792, 1997.
* ↓	C19	Barr, "Vaccines for HIV, HIV therapeutic vaccines: the next phase," <i>GMHC's Treat. Iss.</i> , Vol. 7, No. 5, 1993.
* ↓	C20	Bender <i>et al.</i> , "Inactivated influenza virus, when presented on dendritic cells, elicits human cd8 <sup>+</sup> cytolytic t cell responses," <i>J. Exp. Med.</i> , 12:1663-1671, 1995.
* ↓	C21	Berger <i>et al.</i> , "A new classification of HIV-1," <i>Nature</i> , 391:340, 1998.
* ↓	C22	Blauvelt <i>et al.</i> , "Productive infection of dendritic cells by hiv-1 and their ability to capture virus are mediated through separate pathways," <i>The J. of Clin. Invest.</i> , 100:2043-2053, 1997.
* ↓	C23	Bolognesi and Matthews, "Viral envelope fails to deliver?," <i>Nature</i> , 391:638-639, 1998.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 22, 2003

Group:

1648

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C24	Bombil <i>et al.</i> , "A promising model of primary human immunization in human-scid mouse," <i>Immunobiology</i> , 195:360-375, 1996 (Abstract).
*	C25	Borkow <i>et al.</i> , "Chemical barriers to human immunodeficiency virus type 1 (hiv-1) infection: retroviral activity of uc781, a thiocarboxanilide nonnucleoside inhibitor of hiv-1 reverse transcriptase," <i>J. of Virol.</i> , 71:3023-3030, 1997.
*	C26	Borkow <i>et al.</i> , "Chemical barriers to Human Immunodeficiency Virus type 1 (HIV-1) infection: retroviral activity of UC781, a thiocarboxanilide nonnucleoside inhibitor or HIV-1 reverse transcriptase," <i>Journal of Virology</i> 71(4):3023-3030, 1997.
*	C27	Borkow <i>et al.</i> , "Inhibition of the ribonuclease H and DNA polymerase activities of hiv-1 reverse transcriptase by n-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone," <i>Biochemistry</i> , Abstract, 36(11):3179-3185, 1997.
*	C28	Bryson <i>et al.</i> , "Clearance of HIV infection in a perinatally infected infant," <i>The New Engl. J. of Med.</i> , 332:833-838, 1995.
*	C29	Buckheit <i>et al.</i> , "Efficacy pharmacokinetics and in vivo anti-HIV activity of the highly potent oxathiin carboxanilide analog, UC781," <i>Journal of Molecular Medicine</i> 75(7):b212-b213, 1997.
*	C30	Buckheit <i>et al.</i> , "Efficacy, Pharmacokinetics, and in Vivo Antiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1," <i>Aids Res. and Hu. Retro.</i> , 13:789-796, 1997.
*	C31	Burr, "Of AIDS and altruism," <i>U.S. Nws. &amp; W. Rpt.</i> , pp. 59-61, April 6, 1998.
*	C32	Burton and Montefiori, "The antibody response in HIV-1 infection," <i>Aids</i> , 11:S87-S98, 1997.
*	C33	Cao <i>et al.</i> , "Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection," <i>The New Engl. J. of Med.</i> , 332:201-216, 1995.
*	C34	Carlson <i>et al.</i> , "Vaccine Protection of Rhesus Macaques Against Simian Immunodeficiency Virus Infection," <i>AIDS Res. and Hum. Retroviruses</i> , 6:1239-1246, 1990.
*	C35	Cavert and Haase, "A national tissue bank to track HIV eradication and immune reconstitution," <i>Science</i> , 280:1865-1866, 1998.
*	C36	Cella <i>et al.</i> , "Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells," <i>Nature</i> , 388:782-792, 1997.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.

RIOS:004USC2

Serial No.

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Gr up:

1648

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
* C37	C37	Chowdhry, "Photoaffinity labeling of biological systems," <i>Ann. Rev. Biochem.</i> , 48:293-325, 1979.
* C38	C38	Clerici <i>et al.</i> , "HIV-specific t-helper activity in seronegative health care workers exposed to contaminated blood," <i>JAMA</i> , 271:42-46, 1994.
* C39	C39	Clotet <i>et al.</i> , "Long-term survivors of human immunodeficiency virus type I infection," <i>The New England Journal of Medicine</i> , 332(24):1646-1647, 1995.
* C40	C40	Cohen <i>et al.</i> , "Characterization of the binding site for nevirapine (bi-rg-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase," <i>J. of Biol. Chem.</i> , 266:14670-14674, 1991.
* C41	C41	Collins <i>et al.</i> , "HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes," <i>Nature</i> , 391:397-402, 1998.
* C42	C42	Colonna, "Unmasking the killer's accomplice," <i>Nature</i> , 391:642-644, 1998.
* C43	C43	Constant and Bottomly, "Induction of TH1 and TH2 CD4 <sup>+</sup> T cell responses: the alternative approaches," <i>Annu. Rev. Immunol.</i> , 15:297-322, 1997.
* C44	C44	Daniel, <i>et al.</i> , "A role for DNA-PK in retroviral DNA integration," <i>Science</i> , 284:644-647, 1999.
* C45	C45	DeNoon, "AIDS Therapies: new integrase inhibitor enhances other anti-HIV drugs," <i>AIDS WEEKLY Plus</i> , November 23, 1998, Abstract.
* C46	C46	Doherty and Zinkernagel, "A Biological role for the major histocompatibility antigens," <i>The Lancet</i> , 1406-1409, 1975.
* C47	C47	Doherty and Zinkernagel, "The Specificity of the Cell Mediated Immune Defense," <i>The Nobel Assembly at the Karolinska Institute</i> , Press Release October 7, 1996.
* C48	C48	Dragic <i>et al.</i> , "HIV co-receptors: gateways to the cell," <i>HIV Advances in Research and Therapy</i> , 7(3):2-12, 1997.
* C49	C49	D'Souza <i>et al.</i> , "Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies," <i>AIDS</i> , 9:867-874, 1995.
* C50	C50	Dutton <i>et al.</i> , "T cell memory," <i>Annu. Rev. Immunol.</i> , 16:201-223, 1998.
* C51	C51	Emerman and Malim, "HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology," <i>Science</i> , 280:1880-1884, 1998.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.  
RIOS:004USC2Serial No.  
10/667,534

List of Patents and Publications for Applicant's

Applicant  
Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
September 22, 2003Group: 1648  
~~Unknown~~U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
* ↓	C52	Excler and Plotkin, "The prime-boost concept applied to HIV preventive vaccines," <i>Aids</i> , 11:S127-S137, 1997.
↓	C53	Ferrari, "Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1396-1401, 1997.
↓	C54	Fletcher <i>et al.</i> , "Carboxanilide derivative non-nucleoside inhibitors of hiv-1 reverse transcriptase interact with different mechanistic forms of the enzyme," <i>Biochem.</i> , 34:4346-4353, 1995.
↓	C55	Fletcher <i>et al.</i> , "Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme," <i>Biochemistry</i> 34(13):4346-4353, April 4, 1995.
↓	C56	Frankel and Young, "HIV-1: fifteen proteins and an RNA," <i>Annu. Rev. Biochem.</i> , 67:1-25, 1998.
↓	C57	Gibbons <i>et al.</i> , "Thy/Liv-SCID-Hu mice implanted with human intestine: an <i>in vivo</i> model for investigation of mucosal transmission of HIV," <i>Aids Res. and Hum. Retrovir.</i> , 13:1453-1460, 1997.
↓	C58	Glenn <i>et al.</i> , "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391:851, 1998.
↓	C59	Gotch <i>et al.</i> , "New observations on cellular immune responses to HIV and T-cell epitopes," <i>Aids</i> , 11:S99-S107, 1997.
↓	C60	Graham and Wright, "Drug therapy, candidate aids vaccines," <i>Drug Ther.</i> , 333:1331-1339, 1995.
↓	C61	Guidotti, <i>et al.</i> , "Viral clearance without destruction of infected cells during acute HBV infection," <i>Science</i> , 284:825-829, 1999.
↓	C62	Hahn, "Viral Genes and Their Products," <i>Textbook of AIDS Medicine</i> , Chapter 3, pp. 21-43, Brothier <i>et al.</i> , eds., Williams & Wilkins, Baltimore, MD, 1994.
↓	C63	Hargrave <i>et al.</i> , "Novel non-nucleoside inhibitors of hiv-1 reverse transcriptase, 1. tricyclic pyridobenzo- and dipyridodiazepinones," <i>J. of Med. Chem.</i> , 34:2231-2241, 1991.
↓	C64	Harouse, <i>et al.</i> , "Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs," <i>Science</i> , Internet: www.sciencemag.org, 1999.
↓	C65	Ho, "Toward HIV eradication or remission: the tasks ahead," <i>Science</i> , 280:1866-1867, 1998.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.  
RIOS:004USC2Serial No.  
10/667,534Applicant  
Adan RiosFiling Date:  
September 22, 2003Group:  
Unknown 1648U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C66	Hong <i>et al.</i> , "Discovery of HIB-1 integrase inhibitors by pharmacophore searching," <i>J. Med. Chem.</i> , 40:930-936, 1997, Abstract.
	C67	Huang <i>et al.</i> , "Effect of mutations in the nucleocapsid protein (NCP7) upon PR160(GAG-POL) and trna (lys) incorporation into human immunodeficiency virus type 1," <i>J. of Virology</i> , 71(6):4378-4384, 1997, Abstract.
	C68	Huston, "The biology of the immune system," <i>JAMA</i> , 278:1804-1813, 1997.
	C69	Jawetz eds., <i>et al.</i> , "Serologic diagnosis & immunologic detection of virus infections," <i>Lange Medical Book</i> , 17th ed., Appleton & Lange, Norwalk, CT, pp. 371-380, 1987.
	C70	Jing <i>et al.</i> , "Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide," <i>J. Biomol Struct. Dyn.</i> , 15:573-583, 1997, Abstract.
	C71	Jockusch <i>et al.</i> , "Photo-induced inactivation of viruses: adsorption of methylene blue, thionine, and thiopyronine on Q $\beta$ bacteriophage," <i>Proc. Natl. Acad. Sci. USA</i> , 93:7446-7451, 1996.
	C72	Kim <i>et al.</i> , "Limitation of Hu-PBL-scld mouse model in direct application to immunotoxicity assessment," <i>J. Pharmacol Toxicol Methods</i> , 37:83-89, 1997 (Abstract).
	C73	Knight and Patterson, "Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology," <i>Annu. Rev. Immunol.</i> , 15:593-615, 1997.
	C74	Kollmann <i>et al.</i> , "Disseminated human immunodeficiency virus 1 (hiv-1) infection in scid-hu mice after peripheral inoculation with hiv-1," <i>J. Exp. Med.</i> , 179:513-522, 1994.
	C75	Korber, <i>et al.</i> , "Limitations of a molecular clock applied to considerations of the origin of HIV-1," <i>Science</i> , 280:1868-1871, 1998.
	C76	LaCasse <i>et al.</i> , "Fusion-competent vaccines: broad neutralization of primary isolates of HIV," <i>Science</i> , 283:357-362, 1999.
	C77	Lamb-Wharton <i>et al.</i> , "Primate models of AIDS vaccine development," <i>Aids</i> , 11(suppl A):S121-S126, 1997.
	C78	Lanzavecchia, "Licence to kill," <i>Nature</i> , 393:413-414, 1998.
	C79	Letvin, "Progress in the development of an HIV-1 vaccine," <i>Science</i> , 280:1875-1880, 1998.
	C80	Letvin, "Vaccines against human immunodeficiency virus - progress and prospects," <i>N.E. J. of Med.</i> , 329:1400-1405, 1993.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.

RIOS:004USC2

Serial No.

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Group:

1648

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C81	Lin <i>et al.</i> , "Photoaffinity labeling by 4-thiodideoxyuridine triphosphate of the HIV-1 reverse transcriptase active site during synthesis," <i>J. Bio. Chem.</i> , 273:997-1002, 1998.
	C82	Loetscher <i>et al.</i> , "CCR5 is characteristic of Th1 lymphocytes," <i>Nature</i> , 391:344-345, 1998.
	C83	Long, "Signal sequences stop killer cells," <i>Nature</i> , 391:740-741, 1998.
	C84	Luster, "Chemokines - chemotactic cytokines that mediate inflammation," <i>New Engl. J. of Med.</i> , 338:436-445, 1998.
	C85	Martinez, "Positive + Positive: Sex and the risk of reinfection," <i>Center for AIDS Hope &amp; Remembrance</i> , 3(6):3-5, 1997.
	C86	Matthews <i>et al.</i> , "Preliminary studies of photoinactivation of human immunodeficiency virus in blood," <i>Transfusion</i> , 31:636-641, 1991.
	C87	Mazumder <i>et al.</i> , "Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action," <i>J. Med. Chem.</i> , 40:3057-3063, 1997, Abstract.
	C88	McIntosh and Burchett, "Clearance of HIV-lessons from newborns," <i>The New Engl. J. of Med.</i> , 332:883-884, 1995.
	C89	McMichael and Phillips, "Escape of human immunodeficiency virus from immune control," <i>Annu. Rev. Immunol.</i> , 15:271-296, 1997.
	<del>C90</del>	<del>Meldorf and Corey, "HIV vaccines: combination and prime-boost strategies," <i>HIV</i>, Vol. 7, No. 1, pp. 24-29.</del>
*	C91	Montefiori and Moore, "Magic of the occult?," <i>Science</i> , 283:336-337, 1999.
	C92	Murphy <i>et al.</i> , "The huPBL-SCID mouse as a means to examine human immune function in vivo," <i>Semin Immunol.</i> , 8:233-241, 1996 (Abstract).
	C93	Musey <i>et al.</i> , "Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," <i>The New England J. of Med.</i> , 337:1267-1274; 1305-1308, 1997.
	C94	Namikawa <i>et al.</i> , "Infection of the SCID-hu mouse by HIV-1," <i>Science</i> , 242-1684-1686, 1988.
	C95	NIMH Trial Group, "The NIMH multisite HIV prevention trial: reducing HIV sexual risk behavior," <i>Science</i> , 280:1889-1894, 1998.

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED:

04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)		Atty. Docket No. RIOS:004USC2	Serial No. 10/667,534
List of Patents and Publications for Applicant's		Applicant Adan Rios	
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents See Page 1		Foreign Patent Documents See Page 1	Filing Date: September 22, 2003
		Group: <del>Unknown</del>	1648
		Other Art See Page 1	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Ref. Des.	Citation
C96	Pamer and Cresswell, "Mechanisms of MHC class I-restricted antigen processing," <i>Annu. Rev. Immunol.</i> , 16:323-358, 1998.
C97	Pantaleo <i>et al.</i> , "Studies in subjects with long-term nonprogressive human immunodeficiency virus infection," <i>N. Engl. J. Med.</i> , 332(4):209-216, 1995.
C98	Pauwels <i>et al.</i> , "Potent and selective inhibition of HIV-1 replication <i>in vitro</i> by a novel series of TIBO derivatives," <i>Letters To Nature</i> , 343:470-474, 1990.
C99	Peeters <i>et al.</i> , "Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire," <i>Lancet</i> , 340:339-340, 1992.
C100	Perrin and Telenti, "HIV treatment failure: testing for HIV resistance in clinical practice," <i>Science</i> , 280:1871-1873, 1998.
C101	Phoolcharoen, "HIV/aids prevention in Thailand: success and challenges," <i>Science</i> , 280:1873-1874, 1998.
C102	Quinn, "Acute primary HIV infection," <i>JAMA</i> , 278:58-62, 1997.
C103	Ren <i>et al.</i> , "Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives," <i>Biochem.</i> , 37:14394-14403, 1998.
C104	Ridge <i>et al.</i> , "A conditioned dendritic cell can be a temporal bridge between a CD4 <sup>+</sup> T-helper and a T-killer cell," <i>Nature</i> , 393:473-483, 1998.
C105	Robinson, "DNA vaccines for immunodeficiency viruses," <i>Aids</i> , 11:S109-S119, 1997.
C106	Robinson, "L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the <i>in vitro</i> anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350)," <i>Antiviral Res.</i> , 39:101-111, 1998, Abstract.
C107	Rosenberg <i>et al.</i> , "Vigorous HIV-1-specific cd4 <sup>+</sup> t cell responses associated with control of viremia," <i>Science</i> , 278:1447-1450, 1997.
C108	Rossio <i>et al.</i> , "Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Patterns," <i>J. Virology</i> , 72(10):7992-8001, 1998.
C109	Roth <i>et al.</i> , "Synthesis and biological activity of novel nonnucleoside inhibitors of hiv-1 reverse transcriptase. 2-aryl-substituted benzimidazoles," <i>J. of Med. Chem.</i> , 40:4199-4205, 1997.

25356361.1

EXAMINER: /Jeffrey Parkin/ DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Gr up:

1648

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C110	Schacker <i>et al.</i> , "Annals of internal medicine, biological and virologic characteristics of primary HIV infection," <i>Ann. Intern. Med.</i> , 128:613-620, 1998.
	C111	Schnitz <i>et al.</i> , "Control of viremia in simian immunodeficiency virus infection by cd8 <sup>+</sup> lymphocytes," <i>Science</i> , 283:857-860, 1999.
	C112	Schultz, "Changing paradigms for an HIV vaccine," <i>In: Adv. in Exper. Med. and Biol.</i> , 397:79-90, 1996.
	C113	Schumacher, "Immunology: accessory to murder," <i>Nature</i> , 398:26-27, 1999.
	C114	Sigal <i>et al.</i> , "Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen," <i>Nature</i> , 398:77-80, 1999.
	C115	Smart, "The first integrase inhibitor," <i>GMHC Treat Issues</i> , 10:8-9, 1996, Abstract.
	C116	Smerdon <i>et al.</i> , "Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci., USA</i> , 91:3911-3915, 1994.
	C117	Suhadolnik <i>et al.</i> , "Photolabeling of the enzymes of the 2-5A synthetase/RNase L/p68 kinase antiviral systems with azido probes," <i>Progress in Molecular and Subcellular Biology</i> 14:260-275, 1994.
	C118	Sylwester <i>et al.</i> , "CD4 <sup>+</sup> T-Lymphocyte Depletion in Human Lymphoid Tissue Ex Vivo Is Not Induced by Noninfectious Human Immunodeficiency Virus Type 1 Virions," <i>J. Virology</i> , 72(11):9345-9347, 1998.
	C119	Tang and Cyster, "Chemokine up-regulation and activated T cell attraction by maturing dendritic cells," <i>Science</i> , 284:819-822, 1999.
	C120	Tarasiev <i>et al.</i> , "Photochemoinactivation: a way to AIDS vaccine?," America Online: ARIOS927, Vol. 9 Issue/Part/Supplement 1, 1993 (Abstract).
	C121	Walker, "Immunopathogenesis and immune reconstitution in HIV disease," <i>Intl. Aids Soc.-USA</i> , 6:4-7, 1999.
	C122	Wallace <i>et al.</i> , "Preclinical pharmacology of an anti-HIV oligonucleotide," <i>Int. Conf. AIDS</i> , 11:314, 1996, Abstract.
	C123	Watts, "Capture and processing of exogenous antigens for presentation on MHC molecules," <i>Annu. Rev. Immunol.</i> , 15:821-850, 1997.

25356361.1

EXAMINER:

/Jeffrey Parkin/

DATE CONSIDERED:

04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

RIOS:004USC2

10/667,534

Applicant

Adan Rios

Filing Date:

September 22, 2003

Group:

1648

~~Unknown~~

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C124	Wu <i>et al.</i> , "A novel dipyrroldiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site," <i>Biochem.</i> , 30:2022-2026, 1991.
	C125	Wyatt and Sodroski, "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens," <i>Science</i> , 280:1884-1888, 1998.
	C126	Yang <i>et al.</i> , "Neutralizing antibodies against hiv determined by amplification of viral long terminal repeat sequences from cells infected in vitro by nonneutralized virions," <i>J. of Acq. Imm. Defic. Synd. and Hum. Retro.</i> , 17:27-34, 1998.
	C127	Zhang <i>et al.</i> , "Nascent Human Immunodeficiency Virus Type 1 Reverse Transcription Occurs within an Enveloped Particle," <i>J. Virology</i> , 69(6):3675-3682, 1995.
	C128	Zhao, <i>et al.</i> , "Hydrazide-containing inhibitors of HIV-1 integrase," <i>J. Med. Chem.</i> , 40:937-941, 1997, Abstract.
	C129	Zinkernagel and Doherty, "Immunological surveillance against altered self components by sensitized T lymphocytes in lymphocytic choriomeningitis," <i>Nature</i> , 251:547-548, 1974.
	C130	Zinkernagel and Doherty, "MHC-restricted cytotoxic t cells: studies on the biological role of polymorphic major transplantation antigens determining t-cell restriction-specificity, function, and responsiveness," <i>Advan. In Immunol.</i> , New York, Academic Press, 27:51-177, 1979.
	C131	Zinkernagel and Doherty, "Restriction of <i>in vitro</i> T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system," <i>Nature</i> , 248:701-702, 1974.
	<del>C132</del>	<del>PCT Search Report dated July 7, 1999</del>

25356361.1

EXAMINER: /Jeffrey Parkin/

DATE CONSIDERED: 04/25/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./